Loading organizations...
STRM.BIO develops a non-viral, cell-derived delivery platform for safe, targeted, and scalable in vivo genetic medicines. This core technology employs engineered extracellular vesicles to transport gene therapies, overcoming limitations of traditional viral systems and enhancing treatment precision. The company focuses on developing a more accessible approach to advanced genetic treatments for various conditions.
Jonathan Thon, a serial biotech entrepreneur and leader in human cell culture, founded STRM.BIO. His insight stemmed from the critical need for an effective, scalable gene delivery system to broaden gene therapy applications. Thon, leveraging experience from PlateletBio, established the company to pioneer non-viral delivery platforms and translate scientific advancements into clinical solutions.
STRM.BIO’s platform serves patients globally, particularly those with rare diseases, making gene therapy more accessible. The company’s vision is to democratize gene therapy, ensuring transformative genetic medicines reach a wider population and offer solutions for untreatable conditions. This forward-looking approach aims to reshape the landscape of genetic medicine delivery.
STRM has raised $11.0M across 2 funding rounds.
STRM has raised $11.0M in total across 2 funding rounds.
Streamline Health Solutions Inc. (STRM) is a healthcare technology company providing cloud-based SaaS solutions to optimize revenue cycle management for hospitals and health systems in North America.[1][2][5] It offers products like RevID for automated charge reconciliation and eValuator for AI-enhanced coding audits, addressing revenue leakage by ensuring accurate billing, compliance, and reimbursement in value-based care.[1][2] Serving healthcare providers, STRM tackles financial inefficiencies from disparate clinical, administrative, and billing data, with recent growth including new contracts like a 900-bed Texas health system adopting eValuator and additions of its Quality Module for real-time risk scoring.[2]
Streamline Health Solutions, established as a public company (NASDAQ: STRM) with a current market cap of $22.05M and trailing twelve-month revenue of $18.38M, focuses on healthcare IT amid ongoing financial challenges (net income -$9.07M).[2] While specific founding details and founders are not detailed in available sources, the company has evolved to specialize in pre-bill technologies, integrating AI tools like eValuator and RevID to automate audits and reconciliation, building on partnerships with major EHR providers.[1] Pivotal recent moments include securing contracts with large health systems and launching the eValuator Quality Module, signaling adaptation to regulatory and tech demands in healthcare revenue cycles.[2]
(Note: Other entities like STRM.BIO (biotech using EVs for gene therapy) and Strm Music (AI for musicians) share the ticker or name but are distinct private ventures.[3][4][6])
STRM rides the wave of AI-driven healthcare digitization, where value-based care and regulatory pressures amplify needs for revenue optimization amid rising operational costs.[1] Timing aligns with post-pandemic shifts to automated billing and data integration, as hospitals face revenue leakage estimated in billions annually; STRM's pre-bill tech counters this by bridging siloed systems.[1][2] Market forces like EHR adoption and AI advancements favor its scalable SaaS model, influencing the ecosystem through improved financial stability for providers, enabling reinvestment in patient care.[1][5]
STRM's momentum from new eValuator contracts and module expansions positions it for growth in AI-augmented revenue cycle management, potentially narrowing losses as healthcare IT demand surges.[2] Upcoming trends like deeper AI integration for predictive analytics and expanded quality metrics will shape its path, with influence growing via strategic partnerships if it scales beyond current $18M revenue.[1][2] As a nimble player in a high-stakes market, STRM could transform healthcare finances—or face consolidation risks—tying back to its core mission of turning data into reimbursable insights.[1]
STRM has raised $11.0M across 2 funding rounds. Most recently, it raised $8.0M STRM.BIO - Seed in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 7, 2026 | $8M Seed | Recordati | Blue BAY Capital Fund, Boehringer Ingelheim Venture Fund, Delos Capital | Announced |
| Nov 1, 2021 | $3M Seed | — | Chapter ONE Ventures, Index Ventures, NFX, Singular, GUY Podjarny, Jeff Morris, Jeremy YAP, Phillip Chambers | Announced |
STRM has raised $11.0M in total across 2 funding rounds.
STRM's investors include Recordati, Blue Bay Capital Fund, Boehringer Ingelheim Venture Fund, Delos Capital, Chapter One Ventures, Index Ventures, NFX, Singular, Guy Podjarny, Jeff Morris, Jeremy Yap, Phillip Chambers.
